Match tier
Listed
Presence
Current · Arkansas
Last published
2023
Sources
OpenAlex · ORCID
Refreshed
2026-10-03
M
Md Shadiqul Hoque
Role not yet determined Is this you? Add your title
College of Medicine Administration
2 h-index
4 pubs
5 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Md Shadiqul Hoque's research focuses on multiple myeloma, a cancer of plasma cells. His work investigates clinical characteristics and prognostic factors that influence patient outcomes, including the depth of response to treatment, risk status, and molecular subtypes. He has also examined the role of specific therapies and interventions, such as salvage autologous stem cell transplantation in patients refractory to daratumumab, and the feasibility of outpatient stem cell transplantation, identifying risk factors for hospital admission. Additional research includes evaluating nivolumab for advanced, refractory, high-risk multiple myeloma and exploring the prognostic value of various assessment methods like PET-CT and minimal residual disease status. Hoque has collaborated with researchers at the University of Arkansas for Medical Sciences, including Guido Tricot and Sravani Gundarlapalli, on multiple shared publications.
Metrics
- h-index: 2
- Publications: 4
- Citations: 5
Selected Publications
-
In vivo CAR T-cell engineering in B-cell malignancies: A systematic review of emerging clinical and translational evidence. (2026)
-
Participation in a multidisciplinary institutional committee, “RQUEST,” to enhance quality improvement education, project design, and implementation for hematology/oncology fellows. (2023)
-
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)
-
Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance (2021)
-
Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma (2021)
-
Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status (2021)
-
Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM). (2021)
-
Late Relapsing Multiple Myeloma ≥ 10 Years after Treatment on Total Therapy Protocols Are Associated with Good Outcome (2020)
-
Predicting Risk of Progression in Relapsed Multiple Myeloma Using Minimal Residual Disease Status and Focal Lesion Assessment with PET-CT (2020)
-
Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission (2020)
-
Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma (2017)
-
Clinical and Molecular Characterization of Primary Plasma Cell Leukemia (2017)
-
Characteristics and Surgical Success of Patients Presenting for Repair of Genitourinary Fistula in VVF Center of a Tertiary Hospital (2017)
-
The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype (2017)
-
Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease (2017)
Collaboration Network
Top Collaborators
Carolina Schinke
University of Arkansas for Medical Sciences
14 shared publications
In database
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma
Showing 5 of 14 shared publications
Sharmilan Thanendrarajan
University of Arkansas for Medical Sciences
14 shared publications
In database
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma
- Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission
Showing 5 of 14 shared publications
Frits van Rhee
University of Arkansas for Medical Sciences
14 shared publications
In database
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma
Showing 5 of 14 shared publications
Maurizio Zangari
University of Arkansas for Medical Sciences
14 shared publications
In database
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma
Showing 5 of 14 shared publications
Meera Mohan
Froedtert Hospital (US)
12 shared publications
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma
Showing 5 of 12 shared publications
Pankaj Mathur
University of Arkansas for Medical Sciences (US)
10 shared publications
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma
- Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission
Showing 5 of 10 shared publications
Guido Tricot
University of Arkansas for Medical Sciences
8 shared publications
In database
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission
- Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).
- Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
Showing 5 of 8 shared publications
Daisy Alapat
7 shared publications
In database
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
- Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma
- Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Showing 5 of 7 shared publications
Mathew Kottarathara
University of Arkansas for Medical Sciences (US)
7 shared publications
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission
- Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).
- Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
Showing 5 of 7 shared publications
Richa Parikh
University of Arkansas for Medical Sciences (US)
7 shared publications
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission
- Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).
- Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
Showing 5 of 7 shared publications
Angel Mitma
University of Arkansas for Medical Sciences (US)
7 shared publications
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Feasibility of Outpatient Autologous Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predicting Hospital Admission
- Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).
- Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
Showing 5 of 7 shared publications
Sandra P. Susanibar-Adaniya
University of Arkansas for Medical Sciences (US)
6 shared publications
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma
- Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma
- Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma
Showing 5 of 6 shared publications
Muthukumar Radhakrishnan
University of Arkansas for Medical Sciences (US)
6 shared publications
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Nivolumab for Treatment of Advanced, Refractory, High-Risk Multiple Myeloma
- Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma
- Comparison of MRD Detection By MFC, NGS and PET-CT in Patients at Different Treatment Stages for Multiple Myeloma
Showing 5 of 6 shared publications
Sravani Gundarlapalli
University of Arkansas for Medical Sciences
6 shared publications
In database
- Salvage Autologous Stem Cell Transplantation in Daratumumab-Refractory Multiple Myeloma
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Salvage autologous stem cell transplantation in daratumumab refractory multiple myeloma (MM).
- Predicting risk of progression in relapsed multiple myeloma using traditional risk models, focal lesion assessment with PET-CT and minimal residual disease status
- Eight-Color Flow Cytometry Phenotypic Markers and Disease Progression in Monoclonal Gammopathy of Unknown Significance
Showing 5 of 6 shared publications
Bart Barlogie
University of Arkansas for Medical Sciences
5 shared publications
In database
- Clinical characteristics and prognostic factors in multiple myeloma patients with light chain deposition disease
- The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype
- Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission
- Next Generation Sequencing (NGS) Based Minimal Residual Disease (MRD) Testing Is Highly Predictive of Overall and Progression Free Survival in the Total Therapy Trials and Shows Different Prognostic Implications in High Vs Standard Risk Multiple Myeloma
- Clinical and Molecular Characterization of Primary Plasma Cell Leukemia
Similar Researchers
Based on overlapping research topics
Medhavi Honhar
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Jordan Lee Cottrell
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Cancer Treatment and Pharmacology
Retrospective Studies
Frits Vanrhee
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Amisha Fnu
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
O. Makhoul
University of Arkansas for Medical Sciences
Multiple Myeloma Research and Treatments
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Ankur Varma
University of Arkansas for Medical Sciences
Hematopoietic Stem Cell Transplantation
Cancer Treatment and Pharmacology
Retrospective Studies